GLP-1 Medications and the Future of Healthy Aging: What We Know and What We Don’t

Sep 18

In recent years, medications like Ozempic® (semaglutide) and Saxenda® (liraglutide) have gone from being tools for diabetes care to household names. Newer drugs such as Mounjaro® (tirzepatide) and experimental medicines like retatrutide are showing even stronger effects. These drugs all act on hormones called incretins, which help regulate blood sugar and appetite.

Because they improve metabolism and reduce the risk of serious diseases in diabetics, some people wonder whether these medications could also help us age more healthily or even live longer.

Let’s dive deeper into what we know about these medications, how they work, and why people are connecting them to healthy aging.

Disclaimer: In Canada, these medications are only approved for diabetes and/or weight management and should only be used under medical supervision. This article is for education only and does not constitute medical advice. Please consult your primary care practitioner prior to starting any medication.

How Do GLP-1 Medications Work?

Think of GLP-1 as a natural hormone your body releases after eating. It helps your pancreas release insulin, slows stomach emptying, and tells your brain you’re full.

Drugs like liraglutide, dulaglutide, semaglutide, and exenatide are “first-generation” GLP-1 receptor agonists (GLP-1 RAs). They mimic this hormone, helping people control blood sugar and lose weight.

Newer drugs work on more than one hormone receptor:

Tirzepatide (Mounjaro®, Zepbound®) acts on both GLP-1 and GIP receptors, giving stronger effects.
Retatrutide (still in trials, not Health Canada or FDA approved) acts on three receptors: GLP-1, GIP, and glucagon. It has shown record-breaking weight loss in early studies, but it’s not approved yet (as of September 2025)

Why Are They Being Linked to Longevity?

Healthy aging is about adding years of good health, not just living longer. Many of the diseases that cut life short - like heart disease, kidney disease, dementia, and cancer - are linked to poor metabolic health.

GLP-1 medications may help with:

Blood sugar control (important for preventing diabetes complications).
Weight loss (reducing obesity-related risks).
Heart protection (lowering blood pressure, improving cholesterol, reducing risk of heart attack and stroke in those with diabetes).
Kidney protection (slowing kidney damage in diabetes).

Since they improve conditions that shorten life, it makes sense to ask: could they directly slow aging too in health individuals?

The Role of Inflammation in Aging

Scientists now know that chronic inflammation - sometimes called “inflammaging” - is one of the drivers of biological aging. It is like a constant low-level fire in the body, damaging tissues over time and raising the risk of heart disease, dementia, and other chronic conditions.

Studies show that GLP-1 medications may reduce certain inflammatory signals in the body (Pugazhenthi et al., 2017). They may also lower oxidative stress, which is the buildup of damaging molecules that accelerate cellular aging.

This is promising, but it is important to be cautious:

Most of this evidence comes from animal or lab studies.
In humans, we know they improve inflammation markers indirectly (through weight loss and better blood sugar), but not whether they directly slow aging.

Metabolic Control and Healthy Aging

The ability to manage blood sugar and body fat plays a central role in aging. People with diabetes, obesity, or metabolic syndrome are at higher risk for:

Cardiovascular disease
Kidney disease
Certain cancers
Cognitive decline and dementia

GLP-1 medications may improve metabolic control in several ways:

Lowering blood sugar and HbA1c (a long-term blood sugar marker).
Increasing insulin sensitivity.
Promoting significant, sustainable weight loss.
Improving cholesterol and triglycerides.
Lowering blood pressure.

This broad improvement in metabolic health may explain why they reduce heart attacks, strokes, and kidney disease in large clinical trials (Kristensen et al., 2019; Mann et al., 2017).

What About the Brain?

Brain health is another frontier in aging research. Early studies suggest GLP-1 medications may help protect neurons. In mouse models of Alzheimer’s disease, liraglutide reduced amyloid plaques and improved memory (McClean and Hölscher, 2014).

Some small human studies are underway, but there is not enough evidence to recommend these drugs for brain health or dementia prevention.

What They Do Not Do

Despite all the excitement, here’s what these medications do not do, based on current evidence:

They do not extend human lifespan.
They do not stop aging.
They are not approved by Health Canada for anti-aging or longevity.

They should be viewed as powerful treatments for specific medical conditions (diabetes, obesity).

Risks and Safety

Like any medication, GLP-1 drugs come with risks:

Nausea, vomiting, diarrhea (most common).
Gallbladder disease.
Rare cases of pancreatitis.

Bottom Line

GLP-1 medications and newer incretin drugs are revolutionizing diabetes and obesity treatment. They improve blood sugar, reduce weight, lower heart risks, and may protect the kidneys and brain. All of these effects support healthier aging, because they reduce the burden of chronic disease.

In the future, ongoing trials may tell us whether these medications can directly influence the biology of aging. For now, they remain a powerful part of modern medicine’s fight against metabolic disease - a major step toward healthier, but not necessarily longer, lives in those with specific medical issues.

References

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., ... & REWIND Investigators. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
Heise, T., Bain, S. C., Coca, A., & Dungan, K. (2022). Cardiometabolic effects of tirzepatide: Mechanistic insights and clinical implications. Diabetes, Obesity and Metabolism, 24(3), 274–282. https://doi.org/10.1111/dom.14618
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., ... & EXSCEL Study Group. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 377(13), 1228–1239. https://doi.org/10.1056/NEJMoa1612917
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Retatrutide Investigators. (2023). Triple-hormone receptor agonist retatrutide in overweight or obesity. New England Journal of Medicine, 389(1), 11–24. https://doi.org/10.1056/NEJMoa2302394
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., & McMurray, J. J. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists. The Lancet Diabetes & Endocrinology, 7(10), 776–785. https://doi.org/10.1016/S2213-8587(19)30249-9
Mann, J. F., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., ... & LEADER Steering Committee and Investigators. (2017). Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, 377(9), 839–848. https://doi.org/10.1056/NEJMoa1616011
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M., ... & LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
McClean, P. L., & Hölscher, C. (2014). Liraglutide can reverse memory impairment and reduce plaque load in mice with Alzheimer’s disease. Neuropharmacology, 76 Pt A, 57–67. https://doi.org/10.1016/j.neuropharm.2013.08.005
Nauck, M. A., & Meier, J. J. (2019). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 21(Suppl 1), 5–21. https://doi.org/10.1111/dom.13658
Pugazhenthi, S., Qin, L., & Reddy, P. H. (2017). Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(5), 1037–1045. https://doi.org/10.1016/j.bbadis.2016.04.017
Pratley, R. E., Aroda, V. R., Lingvay, I., Ludemann, J., Andreassen, C., Navarria, A., ... & DeVries, J. H. (2018). Semaglutide versus dulaglutide once weekly (SUSTAIN 7). The Lancet Diabetes & Endocrinology, 6(4), 275–286. https://doi.org/10.1016/S2213-8587(18)30024-X
Shi, X., Cai, H., Wang, Q., Fang, X., Wu, J., Zhang, Y., ... & Xu, T. (2019). GLP-1 receptor regulates lifespan and oxidative stress resistance in C. elegans. Aging Cell, 18(2), e12880. https://doi.org/10.1111/acel.12880
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kadowaki, T. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Sam Hetz